{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:01:20Z","timestamp":1774040480694,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":170,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) recurrence rates following locoregional treatment are high. As multireceptor tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFRs) are effective in advanced HCC, we assessed the efficacy and safety of neoadjuvant systemic treatment with dovitinib in early- and intermediate-stage HCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Twenty-four patients with modified Child-Pugh class A early- and intermediate-stage HCC received neoadjuvant oral dovitinib 500 mg daily (5\u2009days on\/2\u2009days off) for 4\u2009weeks, followed by locoregional therapy. Primary endpoints were objective response rates and intratumoral blood flow changes. Secondary endpoints were safety, pharmacodynamical plasma markers of VEGFR-blockade, time to progression (TTP), and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Modified RECIST overall response rate was 48%, including 13% complete remission, and despite dose reduction\/interruption in 83% of patients, intratumoral perfusion index decreased significantly. Grade 3\u20134 adverse events, most frequently (on-target) hypertension (54%), fatigue (25%), and thrombocytopenia (21%), occurred in 88% of patients. Plasma VEGF-A, VEGF-D, and placental growth factor increased significantly, whereas sTie-2 decreased, consistent with VEGFR-blockade. Following neoadjuvant dovitinib, all patients could proceed to their original planned locoregional treatment. No delayed toxicity occurred. Seven patients (three early, four intermediate stage) underwent orthotopic liver transplant after median 11.4 months. Censoring at transplantation, median TTP and OS were 16.8 and 34.8 months respectively; median cancer-specific survival was not reached.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Already after a short 4-week dovitinib treatment period, intratumoral blood flow reduction and modest antitumor responses were observed. Although these results support use of systemic neoadjuvant strategies, the poor tolerability indicates that dovitinib dose adaptations are required in HCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Orthotopic liver transplantation may cure early and intermediate-stage hepatocellular carcinoma. Considering the expected waiting time &amp;gt;6 months because of donor liver scarcity, there is an unmet need for effective neoadjuvant downsizing strategies. Angiogenesis inhibition by dovitinib does not negatively affect subsequent invasive procedures, is safe to administer immediately before locoregional therapy, and may provide a novel treatment approach to improve patient outcomes if tolerability in patients with hepatocellular carcinoma can be improved by therapeutic drug monitoring and personalized dosing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13901","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T15:45:07Z","timestamp":1626104707000},"page":"854-864","source":"Crossref","is-referenced-by-count":28,"title":["Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-6156","authenticated-orcid":false,"given":"F.J. Sherida H.","family":"Woei-A-Jin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden"},{"name":"Department of Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir I.","family":"Weijl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-291X","authenticated-orcid":false,"given":"Mark C.","family":"Burgmans","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-1568","authenticated-orcid":false,"given":"Arantza","family":"Fari\u00f1a Sarasqueta","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-7730","authenticated-orcid":false,"given":"J.","family":"Tom van Wezel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-5242","authenticated-orcid":false,"given":"Martin N.J.M.","family":"Wasser","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minneke J.","family":"Coenraad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-0918","authenticated-orcid":false,"given":"Jacobus","family":"Burggraaf","sequence":"additional","affiliation":[{"name":"Center for Human Drug Research, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Osanto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden"},{"name":"Department of Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"2022012122081044900_onco13901-bib-0001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"suppl 4","key":"2022012122081044900_onco13901-bib-0002","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"2022012122081044900_onco13901-bib-0003","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/liv.12966","article-title":"Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy","volume":"36","author":"Finkenstedt","year":"2016","journal-title":"Liver Int"},{"key":"2022012122081044900_onco13901-bib-0004","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022012122081044900_onco13901-bib-0005","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jhep.2018.12.027","article-title":"Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3cm in potentially transplantable patients","volume":"70","author":"Doyle","year":"2019","journal-title":"J Hepatol"},{"key":"2022012122081044900_onco13901-bib-0006","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2022012122081044900_onco13901-bib-0007","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.28600","article-title":"Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma","volume":"64","author":"Cheng","year":"2016","journal-title":"Hepatology"},{"key":"2022012122081044900_onco13901-bib-0008","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-12-2885","article-title":"Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma","volume":"19","author":"Angevin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022012122081044900_onco13901-bib-0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0091270011433330","article-title":"Population pharmacokinetic\/pharmacodynamic modeling to assist dosing schedule selection for dovitinib","volume":"53","author":"Wang","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2022012122081044900_onco13901-bib-0010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1535-7163.MCT-11-0412","article-title":"Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3","volume":"11","author":"Tai","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2022012122081044900_onco13901-bib-0011","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1158\/0008-5472.CAN-09-4479","article-title":"Targeting fibroblast growth factor receptors blocks PI3K\/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis","volume":"70","author":"Dey","year":"2010","journal-title":"Cancer Res"},{"key":"2022012122081044900_onco13901-bib-0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022012122081044900_onco13901-bib-0013","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"key":"2022012122081044900_onco13901-bib-0014","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hep.24798","article-title":"International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18","volume":"55","author":"Chie","year":"2012","journal-title":"Hepatology"},{"key":"2022012122081044900_onco13901-bib-0015","volume-title":"The EORTC QLQ-c30 scoring manual","author":"Fayers","year":"2001","edition":"3rd edition"},{"key":"2022012122081044900_onco13901-bib-0016","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1634\/theoncologist.2013-0114","article-title":"Alternative response criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"19","author":"Ronot","year":"2014","journal-title":"The Oncologist"},{"key":"2022012122081044900_onco13901-bib-0017","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022012122081044900_onco13901-bib-0018","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-13-3006","article-title":"Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer","volume":"20","author":"Escudier","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022012122081044900_onco13901-bib-0019","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/cvr\/cvz022","article-title":"Vascular cardio-oncology: Vascular endothelial growth factor inhibitors and hypertension","volume":"115","author":"Versmissen","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2022012122081044900_onco13901-bib-0020","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","article-title":"Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma","volume":"17","author":"Kim","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022012122081044900_onco13901-bib-0021","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022012122081044900_onco13901-bib-0022","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4143\/crt.2017.438","article-title":"Phase II study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05)","volume":"50","author":"Choi","year":"2018","journal-title":"Cancer Res Treat"},{"key":"2022012122081044900_onco13901-bib-0023","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/bjc.2017.290","article-title":"Dovitinib in patients with gastrointestinal stromal tumour refractory and\/or intolerant to imatinib","volume":"117","author":"Joensuu","year":"2017","journal-title":"Br J Cancer"},{"key":"2022012122081044900_onco13901-bib-0024","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/bjc.2013.594","article-title":"Phase II study of dovitinib in patients with metastatic and\/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib","volume":"109","author":"Kang","year":"2013","journal-title":"Br J Cancer"},{"key":"2022012122081044900_onco13901-bib-0025","doi-asserted-by":"crossref","first-page":"e1274","DOI":"10.1634\/theoncologist.2019-0718","article-title":"Sorafenib for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosis: Lessons learned from a terminated study","volume":"25","author":"Labeur","year":"2020","journal-title":"The Oncologist"},{"key":"2022012122081044900_onco13901-bib-0026","doi-asserted-by":"crossref","first-page":"791013","DOI":"10.4061\/2011\/791013","article-title":"Liver resection after downstaging hepatocellular carcinoma with sorafenib","volume":"2011","author":"Barbier","year":"2011","journal-title":"Int J Hepatol"},{"key":"2022012122081044900_onco13901-bib-0027","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1478-3231.2010.02441.x","article-title":"Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection","volume":"31","author":"Irtan","year":"2011","journal-title":"Liver Int"},{"key":"2022012122081044900_onco13901-bib-0028","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2022012122081044900_onco13901-bib-0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022012122081044900_onco13901-bib-0030","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022012122081044900_onco13901-bib-0031","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-015-1373-z","article-title":"Impact of neo-adjuvant sorafenib treatment on liver transplantation in HCC patients - A prospective, randomized, double-blind, phase III trial","volume":"15","author":"Hoffmann","year":"2015","journal-title":"BMC Cancer"},{"key":"2022012122081044900_onco13901-bib-0032","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2022012122081044900_onco13901-bib-0033","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2022012122081044900_onco13901-bib-0034","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-017-0712-x","article-title":"The biology of hepatocellular carcinoma: Implications for genomic and immune therapies","volume":"16","author":"Khemlina","year":"2017","journal-title":"Mol Cancer"},{"key":"2022012122081044900_onco13901-bib-0035","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1158\/1078-0432.CCR-11-2322","article-title":"Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib","volume":"18","author":"Lachenmayer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022012122081044900_onco13901-bib-0036","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1158\/1078-0432.CCR-09-2578","article-title":"Inhibition of vascular endothelial growth factor receptor-1\/wnt\/\u03b2-catenin crosstalk leads to tumor cell death","volume":"15","author":"Zeitlin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022012122081044900_onco13901-bib-0037","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1634\/theoncologist.2017-0479","article-title":"Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma","volume":"23","author":"Ikeda","year":"2018","journal-title":"The Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13901","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/10\/854\/42256780\/oncolo_26_10_854.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/10\/854\/42256780\/oncolo_26_10_854.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T22:58:36Z","timestamp":1642805916000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/10\/854\/6513545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,8,4]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13901","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,8,4]]}}}